Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“We’re very pleased to share new positive topline results for our antibody-drug conjugate plus PD-1 inhibitor from an additional Phase 3 study in early-stage bladder cancer with Astellas Pharma and Merck.
The trial showed clinically meaningful and statistically significant event-free and overall survival results with our treatment regimen when used before and after surgery in people with muscle-invasive Bladder Cancer (MIBC) who are eligible for cisplatin-based chemotherapy.
These results, combined with the recent unprecedented results from the cisplatin-ineligible MIBC study, showcase the promising future of this regimen as a potential cornerstone of care for bladder cancer regardless of cisplatin eligibility.
I would like to extend my gratitude to the patients, families and investigators who contributed to this key global study, addressing a significant clinical unmet need.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.